Canada: Supreme Court Denies Leave In Takeda Canada Inc. v. Minister of Health, Attorney General of Canada

Last Updated: June 19 2013
Article by Adam Bobker and Matthew Cahill (Summer Student)

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal (the "FCA") decision in Takeda Canada Inc. v. Minister of Health, Attorney General of Canada, 2013 FCA 13. This proceeding arises from the Minister's refusal to list Takeda's drug, DEXILANT, on the Register of Innovative Drugs and provide data protection in accordance with section C.08.004.1 of the Food and Drug Regulations, CRC c 870, as amended by the Regulations Amending the Food and Drug Regulations (Data Protection), SOR/2006-241.

The data protection regulations were enacted to comply with Canada's obligations under Article 1711 of the North American Free Trade Agreement, 1992, 32 ILM 296 ("NAFTA") and paragraph 3 of Article 39 in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 1869 UNTS 299 ("TRIPS"). These agreements require that "...where a person submits undisclosed data for approval of a pharmaceutical product, and the product utilizes a 'new chemical entity', signatory states commit to preventing other persons from making 'unfair commercial use' of that data and (for a reasonable time) from relying on that data in their own applications for approval" (2011 FC 1444, at 13).

The protection granted to innovative drugs under the Canadian data protection regulations takes two forms. "Firstly, a generic drug manufacturer cannot file a submission based on a comparison to an 'innovative drug' within the first six years of the eight-year period after the drug has received a Notice of Compliance ("NOC") (subsection C.08.004.01(3)(a)). Secondly, the Minister may not issue a NOC to the generic drug manufacturer before the end of the eight-year period (subsection C.08.004.01 (3)(b))" (2011 FC 1444, at 12).

DEXILANT is a trade name for dexlansoprazole, a compound intended for use in the treatment of, among other things, gastroesophageal reflux disease ("GERD"). Dexlansoprazole is an enantiomer of lansoprazole. A racemic mixture of the two lansoprazole enantiomers, dexlansoprazole and levlansoprazole, is currently marketed by Takeda as the drug PREVACID, also used for the treatment GERD.

In August of 2009, Takeda Canada Inc. filed a New Drug Submission for DEXILANT. A NOC to market the drug was issued in July 22, 2010. However, the Office of the Patented Medicines and Liaison ("OPML") decided, on behalf of the Minister, that DEXILANT did not meet the definition of "innovative drug" as required by the regulations. The OPML took the position that because dexlansoprazole was an enantiomer of the previously-approved medicinal ingredient lansoprazole, it was a "variation" within the meaning of the Regulations and therefore not eligible for data protection. Takeda applied to the Federal Court (FC) for judicial review of this decision.

The Federal Court dismissed the application for judicial review (2011 FC 1444). Data protection under section C.08.004.1 of the Food and Drug Regulations (the "Regulations") is extended to "innovative drugs". The issue before the Federal Court was whether the Minister erred in interpreting section C.08.004.1(1) of the Food and Drug Regulations which defines an innovative drug as a "drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph." Justice Near held that the Minister was correct in interpreting the regulation to mean that, as an enantiomer of a previously approved medicinal ingredient, dexlansoprazole was not entitled to data protection. This decision was appealed.

The Majority of the FCA upheld the decision of the Federal Court and endorsed the Minister's interpretation of "innovative drug" (2013 FCA 13). The FCA held that the ordinary wording of the Regulations excludes all enantiomers of previously approved medicinal ingredients from qualifying as "innovative drugs".

Writing for the Majority, Justice Dawson noted that Canada's obligations under NAFTA and TRIPS required that the Governor in Council consider what constitutes "new chemical entities" when crafting the data protection regulations. However, it "...was open to the Governor in Council to decide, as a matter of policy, that salts, esters, enantiomers, solvates and polymorphs were not sufficiently different to be "new chemical entities" and that the Court "...ought not to thwart the decision of the Governor in Council as expressed in the definition of 'innovative drug'" (2013 FCA 13, at 131).

Dissenting, Justice Stratas held that the listed categories in the definition of innovative drugs are examples of substances that may be "variations". In his view, a drug should not be automatically excluded from protection solely on the basis that it contains an ingredient that is an enantiomer of a previously approved medicinal ingredient. Under Justice Stratas' interpretation, the data protection regulations extend to medicinal ingredients that have "safety and efficacy characteristics materially different from a previously approved medicinal ingredient" (2013 FCA 13, at 102). That such an ingredient might be an enantiomer would not be determinative. Justice Stratas would have quashed the Minister's decision and remitted the matter to the Minister for redetermination in light of his interpretation of the Regulations.

The decision in this case, and the recent decision in Canada (Health) v. Celgene Inc. ( summary), indicates that Canadian courts are taking a strict approach to the definition of "innovative drug".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Adam Bobker
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.